🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being hailed as a "significant breakthrough" in the battle against drug-resistant strains of the bacteria, according to researchers.

A Global Public Health Issue

Gonorrhoea infections are increasing around the world, with figures suggesting in excess of 82 million infections per year. Especially elevated rates are seen in Africa and nations within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. Across England, cases have hit a historical peak, while figures across Europe in 2023 were triple the level compared to figures for 2014.

“The clearance of novel therapies for gonorrhoea is an important and timely step in the context of rising global incidence, escalating drug resistance and the very limited treatment choices at this time.”

Medical experts are particularly alarmed about the surge in drug-resistant strains. The global health body has designated it as a "critical concern". Ongoing monitoring found that resistance to primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Recent Treatment Options Receive Approval

One new antibiotic, alternatively called a brand name, was cleared by the US FDA in mid-December for use against gonorrhoea. This disease can lead to serious health problems, including infertility. Researchers believe that targeted use of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, created by the pharmaceutical company GSK, also received approval in concurrent days. This treatment, which is employed against UTIs, was demonstrated in studies to be effective against superbug versions of the gonorrhoea bacteria.

A Novel Partnership

This new treatment was the result of a new, not-for-profit approach for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to see it through.

“This approval marks a huge turning point in the treatment of highly resistant gonorrhoea, which until now has been outpacing antibiotic development.”

Testing Outcomes and Worldwide Availability

According to results released by a major medical journal, zoliflodacin cured more than 90% of uncomplicated infections. This puts it on an comparable level with the typical regimen, which involves two antibiotics. The research enrolled hundreds of participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, GARDP has the rights to license and sell the drug in a wide range of regions with limited resources.

Medical professionals on the front lines have expressed positive views. Access to a easy-to-administer therapy like this is described as a "game-changer" for gonorrhoea control. This is viewed as vital to lessen the impact of the disease for individuals and to prevent the spread of extremely resistant gonorrhoea globally.